… Citation17 In a Phase I study of the MEK inhibitor trametinib in combination with the AKT
inhibitor afuresertib in patients with solid tumors and multiple myeloma, continuous daily dosing …

… is another MEK inhibitor approved in combination with a BRAF inhibitor, … of MEK inhibitors
as monotherapy and in combination, and discuss their clinical role in metastatic melanoma …

… metastatic melanoma approved by the US Food and Drug Administration so far, including
BRAF and MEK inhibitors … for BRAF-mutant metastatic melanoma remains under question [27, …

… to the approval of BRAF/MEK inhibitors (BRAF/MEKi) for BRAF V600 -mutant metastatic
melanoma, and we explore the three major effectors of BRAF/MEK inhibitor resistance which are …

… clinical data regarding MEK inhibitors and their role in the treatment of advanced melanoma.
… indicates that single-agent BRAF or MEK inhibitor treatment may not be a desirable option …

… Importance The cutaneous adverse effects of the BRAF inhibitors … in the treatment of
metastatic melanoma have been well reported. The addition of a MEK inhibitor to a BRAF inhibitor …

… clinically investigated patients with melanoma or metastatic melanoma and those that
studied the combinatorial effect of the participants assigned to BRAF and MEK inhibitors, and 3) …

… novel allosteric MEK inhibitor, has changed the interest of MEK inhibitor identification in
BRAF mutant melanoma. Trametinib represents the best activity in any MEK inhibitor evaluated …

… combination therapy of BRAF and MEK inhibition achieved better curative effect and …
inhibition plus MEK inhibition combination therapy and BRAF inhibition monotherapy in melanoma …

… the search terms melanoma, MEK inhibitor, and cobimetinib. A second search was conducted
to identify melanoma guidelines using the terms melanoma and National Comprehensive …